menu
Intellia Therapeutics Head office building

Press Releases

Intellia Therapeutics Doses First Patient in Landmark CRISPR/Cas9 Clinical Trial of NTLA-2001 for the Treatment of Transthyretin Amyloidosis

NTLA-2001: First single-course therapy that potentially halts and reverses ATTR progression
First-ever in vivo CRISPR treatment delivered intravenously to a patient
Read More

Intellia Therapeutics Announces Third Quarter 2020 Financial Results

On track to dose first patient by year-end with NTLA-2001 for the treatment of transthyretin amyloidosis (ATTR) , following regulatory authorization to initiate Phase 1 clinical trial Anticipate s submit ting an IND or IND-equivalent for lead TCR-T cell therapy, NTLA-5001   for the treatment of
Read More

Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2020 Earnings and Company Updates

CAMBRIDGE, Mass. , Oct. 29, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present its third quarter 2020 financial results and operational
Read More

Intellia Therapeutics Receives Authorization to Initiate Phase 1 Clinical Trial of NTLA-2001 for Transthyretin Amyloidosis (ATTR)

NTLA-2001: First single-course therapy that potentially halts and reverses ATTR On track to dose first patient by year-end with a systemically delivered   CRISPR/Cas9-based therapy CAMBRIDGE, Mass. , Oct. 19, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc.
Read More

Intellia Therapeutics Congratulates Co-Founder Jennifer Doudna On Winning the 2020 Nobel Prize in Chemistry for Inventing the Revolutionary CRISPR/Cas9 Genome Editing Technology

CAMBRIDGE, Mass. , Oct. 07, 2020 (GLOBE NEWSWIRE) -- Today, Jennifer Doudna , Ph.D., one of Intellia Therapeutics , Inc.’s scientific co-founders, was awarded the 2020 Nobel Prize in Chemistry for the development of the CRISPR/Cas9 genome editing technology. Dr.
Read More

Intellia Therapeutics Names John F. Crowley to Board of Directors

CAMBRIDGE, Mass. , Oct. 05, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , has appointed John F. Crowley to its Board of Directors. Mr.
Read More

Intellia Therapeutics Presents New Preclinical Data Showing Persistent In Vivo Editing and Durability of Effect Following CRISPR/Cas9-Based Treatment

In Vivo gene knockout and insertion data to be presented at OTS Annual Meeting highlight modularity of Intellia’s platform and potential for variety of single-course therapies, with company’s first systemic treatment (NTLA-2001) expected to enter the clinic by year-end
Read More

Intellia Therapeutics to Present at Chardan’s Virtual 4th Annual Genetic Medicines Conference

CAMBRIDGE, Mass. , Sept. 28, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present at Chardan’s Virtual 4 th Annual Genetic Medicines
Read More

Intellia Therapeutics to Present at Baird’s 2020 Virtual Global Healthcare Conference

CAMBRIDGE, Mass. , Sept. 02, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present at Baird’s 2020 Virtual Global Healthcare Conference on
Read More

Intellia Therapeutics Announces Second Quarter 2020 Financial Results

Submitted first regulatory application to the U.K.’s MHRA to initiate a Phase 1 study of NTLA-2001 for the treatment of transthyretin amyloidosis; on track to dose first patient by year-end Expanded Regeneron collaboration, receiving $100 million through upfront cash and equity investment and
Read More
RSS FEEDS
PRINT PAGE